The ongoing pandemic has made India and its people face a lot of hardships over the past year. The health scare and the closing down of various types of institutions resulted in people travelling back to, or away from, their homes. Keeping the precautions in mind, various countries shut down their travel services to avoid infected people from other regions from entering their own spaces. Soon enough, airlines were suspended and train routes were blocked.
As the conditions have gotten better, people feel the need to travel back again. But now, countries have allowed the influx of new people only after a complete dose of vaccination. Countries like Australia, Canada, the UK, Russia, etc., which previously banned travel under lockdown, have gradually opened up. All this has been made possible due to the invention of vaccines.
In a news release by WHO on December 31st, 2020, they announced that the Comirnaty COVID-19 mRNA vaccine has been listed for emergency use. Hence, Pfizer-BioNTech has become the first vaccine with emergency validation from WHO since the outbreak started a year ago. Later, it was provided in the UK by the government due to an increased number of cases.
Since then, WHO has authorised another vaccine, AstraZeneca's Covisheild under the COVAX Facility. The serum institute of India has regulated the supply of this vaccine to many countries across the world. Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), said in a communication to the Centre on Monday that the company has increased its In October, Covishield's production capacity will allow it to offer 21.90 crore doses to the Indian government and private institutions.
The next verified vaccine was Bharat Biotech’s Covaxin. It is India’s first selfmade COVID-19 vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The vaccine gained DCGI permission for human clinical trials, which began in July 2020 across India. Based on preliminary trial results, Bharat Biotech predicts that Covaxin will be at least 60% effective. (TOI)
Up until now, Canada had only recognised Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson for its vaccinated travellers up until now. Starting November 30, vaccinations will be required for travel within and outside of Canada. A valid COVID-19 molecular test will no longer be considered as an alternative to vaccination unless passengers meet one of the few exceptions, such as a medical inability to get vaccinated. Passengers should contact their airline or train company to receive the required form and submit it in accordance with their carrier's clearance process by November 30, a spokesman for the Canadian government said, providing confidence and relief to the travellers. On November 19, a representative of the Canadian government said, "Passengers should contact their airline or railway company to receive the relevant form and submit it in accordance with their carrier's approval process by November 30," thereby providing assurance and relief to the travellers.
Share This Post On
Leave a comment
You need to login to leave a comment. Log-in